CA2706933C - Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse - Google Patents

Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse Download PDF

Info

Publication number
CA2706933C
CA2706933C CA2706933A CA2706933A CA2706933C CA 2706933 C CA2706933 C CA 2706933C CA 2706933 A CA2706933 A CA 2706933A CA 2706933 A CA2706933 A CA 2706933A CA 2706933 C CA2706933 C CA 2706933C
Authority
CA
Canada
Prior art keywords
nanoparticles
derivative
active
solubility
squalene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2706933A
Other languages
English (en)
French (fr)
Other versions
CA2706933A1 (fr
Inventor
Patrick Couvreur
Harivardhan Reddy Lakkireddy
Franco Dosio
Luigi Cattel
Barbara Stella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Paris-Sud
Original Assignee
Centre National de la Recherche Scientifique
Université Paris-Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Université Paris-Sud filed Critical Centre National de la Recherche Scientifique
Publication of CA2706933A1 publication Critical patent/CA2706933A1/fr
Application granted granted Critical
Publication of CA2706933C publication Critical patent/CA2706933C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2706933A 2007-11-27 2008-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse Active CA2706933C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0708296A FR2924024B1 (fr) 2007-11-27 2007-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
FR0708296 2007-11-27
PCT/FR2008/052147 WO2009071850A2 (fr) 2007-11-27 2008-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse

Publications (2)

Publication Number Publication Date
CA2706933A1 CA2706933A1 (fr) 2009-06-11
CA2706933C true CA2706933C (fr) 2016-07-05

Family

ID=39521786

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2706933A Active CA2706933C (fr) 2007-11-27 2008-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse

Country Status (7)

Country Link
US (1) US8962552B2 (enExample)
EP (1) EP2219678B1 (enExample)
JP (1) JP5520228B2 (enExample)
CN (1) CN101925365B (enExample)
CA (1) CA2706933C (enExample)
FR (1) FR2924024B1 (enExample)
WO (1) WO2009071850A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937537A1 (fr) 2008-10-29 2010-04-30 Centre Nat Rech Scient Nanoparticules de statine
EP2344277B1 (en) * 2008-10-31 2018-06-27 Hitachi Koki CO., LTD. Centrifuge
EP2393472B1 (en) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
FR2988092B1 (fr) 2012-03-16 2014-04-25 Centre Nat Rech Scient Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique
CN104427977B (zh) 2012-05-10 2018-02-02 佩因拉佛姆有限公司 局部麻醉剂的储库制剂及其制备方法
CN103421085B (zh) * 2012-05-18 2015-07-29 中国科学院上海药物研究所 用于增加紫杉醇或以紫杉醇结构为基础的类似药物的溶解度的寡肽
CN103351424B (zh) * 2013-06-09 2016-05-04 东南大学 一种紫杉醇或多烯紫杉醇奥曲肽偶联物的制备方法
CN107073132B (zh) * 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
HUE055079T2 (hu) * 2015-10-07 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Pirimidin vegyületek
EP3598982A1 (en) * 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives
AU2019311965B2 (en) 2018-07-23 2026-02-19 Japan Institute For Health Security Composition containing influenza vaccine
FR3110427B1 (fr) 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage
JP2025535561A (ja) * 2022-12-19 2025-10-24 元樟生物科技股▲フン▼有限公司 薬物リンカーおよびリンカー共役化合物
CN119613473B (zh) * 2024-12-06 2026-02-27 大连医科大学 阿霉素-角鲨烯小分子前药及其制备方法和应用
CN120210296B (zh) * 2025-03-27 2026-05-26 安徽天寅生物技术有限公司 一种纳米级水溶性角鲨烯的制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02204489A (ja) * 1989-02-02 1990-08-14 Ajinomoto Co Inc 易溶性２’，３’―ジデオキシイノシン、その製造法及び２’，３’―ジデオキシイノシン水性溶液の製造法
US5489589A (en) * 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
GB9718791D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Medicaments
CA2371912C (en) * 1999-05-21 2010-02-16 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
US20050100577A1 (en) 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
US20060198940A1 (en) * 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance

Also Published As

Publication number Publication date
WO2009071850A8 (fr) 2009-09-17
CN101925365A (zh) 2010-12-22
CN101925365B (zh) 2013-03-06
WO2009071850A2 (fr) 2009-06-11
US8962552B2 (en) 2015-02-24
EP2219678A2 (fr) 2010-08-25
US20100305030A1 (en) 2010-12-02
EP2219678B1 (fr) 2021-05-19
FR2924024B1 (fr) 2012-08-17
CA2706933A1 (fr) 2009-06-11
WO2009071850A3 (fr) 2009-11-26
JP5520228B2 (ja) 2014-06-11
FR2924024A1 (fr) 2009-05-29
JP2011506276A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
EP2219678B1 (fr) Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
EP2055711B1 (fr) Utilisation de l'acide squalénique pour la formulation d'un principe actif à l'état de nanoparticules
Wang et al. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines
JP2852421B2 (ja) 燐脂質類に対し、そして少くとも一種類の燐脂質に対して親和性を有する活性物質から成る微結晶、並びにその製造方法及びこの微結晶を含有する薬剤組成物
EP3812376A1 (en) Paclitaxel-lipid-polysaccharide dual-type conjugate, preparation method therefor and use thereof
HU213200B (en) The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
EP2435031B1 (fr) Formulations à compartiments multiples à base de molécules ou macromolécules amphiphiles fonctionnelles
EP2297176B1 (fr) Nouveau systeme de transfert d'acide nucleique
WO2004043993A2 (fr) Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
WO1997033919A1 (fr) Thioureido-cyclodextrines, utilisables en particulier pour solubiliser des agents antitumoraux et antiparasitaires et leurs procedes de preparation
EP1429810A1 (fr) Vectorisation de derives taxoides a travers la barriere hematoencephalique
EP2825531B1 (fr) Conjugués de vitamine c
WO2004075922A2 (fr) Composes comprenant au moins une substance active et au moins un vecteur relies par un agent de liaison, leurs utilisation et lesdits agents de liaison
WO2022238568A1 (fr) Prodrogue nucléolipidique antioxydante, composition pharmaceutique pour son administration et leurs utilisations thérapeutiques

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119